Observational studyJournal of perinatology : official journal of the California Perinatal Association2021
Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study.
Observational study in Journal of perinatology : official journal of the California Perinatal Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Predictors of Failure of Conventional Dose Caffeine Therapy in Neonates Below 32 Weeks' Gestation: An Ambispective Cohort Study.Indian journal of pediatrics · 2026Article
- Personalization of Caffeine Therapy for Apnea of Prematurity: A Potential Role for Sensor Technologies?Sensors (Basel, Switzerland) · 2026Review
- Association of caffeine citrate plus vitamin A/D drops with bronchopulmonary dysplasia and respiratory outcomes in preterm infants born at <32 weeks' gestation: a 72-h landmark retrospective cohort study.Frontiers in pediatrics · 2026Article
- Caffeine use in preterm neonates: national insights into Turkish NICU practices.Frontiers in pediatrics · 2025Article
- Effect of caffeine citrate on diaphragmatic electrical activity in pre-term newborns.PloS one · 2025Observational
- [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCaffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity. There is no accepted consensus regarding the optimal caffeine citrate dosing. In this study, we evaluate clinical responses of premature neonates to standard-dose caffeine citrate treatment.
methodsA prospective observational study conducted at the NICU at Sheba Medical Center (3/2016-2/2017). The study population included preterm neonates born at a gestational age (GA) < 33 weeks and treated with caffeine citrate according to the local NICU protocol.
resultsThe study cohort included 66 preterm neonates of GA < 33 weeks. Thirty infants were defined as responders and 36 as nonresponders to 7.5 mg/kg caffeine citrate treatment, and they required a further dose increase to 10 mg/kg. Infants in the nonresponders group were born at earlier GA than responders (29 vs. 31 weeks, respectively, P = 0.004). The nonresponders required a significantly longer hospital stay (56 vs. 46 days, P = 0.014), and longer supplemental oxygen support (18 vs 2 days, P = 0.008).
conclusionsCaffeine citrate initiation at higher doses is safe and does not require routine serum levels monitoring. It might be more effective for controlling apnea of prematurity in preterm neonates born ≤29 weeks of gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.